Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Oropharyngeal Neoplasms 3Myelodysplastic Syndromes 3Leukemia 3Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma of Lung 2Warts 1Vasculitis 1Urinary Bladder Neoplasms 1Spinal Cord Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Renal Pelvis and Ureter Urothelial Carcinoma × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡